Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs

  • Lantheus Holdings Inc LNTH has licensed POINT Biopharma Global Inc's PNT PNT2002 and PNT2003 product candidates.
  • Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on FDA approval and net sales and commercial milestones. 
  • Additionally, Lantheus will pay POINT royalties on net sales of 20% for PNT2002 and 15% for PNT2003. 
  • The agreements expand Lantheus' radiopharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT2002, broadens Lantheus' prostate cancer franchise. 
  • PNT2002 is a PSMA-targeted 177Lu-based radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC).
  • PNT2002 is currently in its Phase 3 study designed to evaluate superiority to the standard of care in mCRPC pre-chemotherapy patients who have failed one androgen receptor pathway inhibitor.
  • PNT2003 is a somatostatin receptor (SSTR) targeted radioligand therapy with no-carrier-added 177Lu, in development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PNT2003 is currently in a Phase 3 trial.
  • Price Action: PNT shares are down 34.6% at $5.98, and LNTH shares are up 0.02% at $56.48 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!